Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 7/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.32 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15931994 | 0.80 | PARP1 (0.33) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL21163476 | 0.77 | POLB (0.38) | — | |
| SCHEMBL16464351 | 0.76 | HTT (0.48) | — | |
| SCHEMBL16464352 | 0.76 | HTT (0.48) | — | |
| SCHEMBL16464353 | 0.76 | HTT (0.48) | — | |
| SCHEMBL13844344 | 0.72 | CHRM2 (0.44) | KRASCHRM2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20292111 | 0.71 | SLC6A2 (0.42) | KRASCHRM2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL661466 | 0.70 | SLC6A2 (0.41) | KRASCHRM2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL661939 | 0.70 | SLC6A2 (0.41) | KRASCHRM2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL660453 | 0.70 | SLC6A2 (0.41) | KRASCHRM2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | KRAS 3213/4885CHRM2 591/4885SLC6A2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.